EPI-7386

DRUG3 trials

Sponsors

Essa Pharma Inc., Janssen Research & Development, LLC, Pedro Barata, MD, MSc

Conditions

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Metastatic castration-resistant prostate cancerProstate AdenocarcinomaProstate CancerProstatic Neoplasms

Phase 1

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

TerminatedNCT05295927

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2022-03-23End: 2022-09-30Updated: 2025-02-03

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

CompletedCTIS2023-509336-25-00

Essa Pharma Inc.Metastatic castration-resistant prostate cancer

Start: 2024-06-12End: 2024-10-31Target: 50Updated: 2024-10-01

Phase 2

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

CompletedNCT06312670

Pedro Barata, MD, MScMetastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Adenocarcinoma, Prostate Cancer

Start: 2024-05-16End: 2025-01-09Updated: 2025-05-29

Related Papers

EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide for patients with treatment-naïve metastatic hormone-sensitive prostate cancer.

2025-12-30